Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Shares Outstanding (Weighted Average) (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 209.67% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Sep 2025, up 209.67%, and an annual FY2024 reading of $701749.0, up 5371.73% over the prior year.
  • Shares Outstanding (Weighted Average) was $3.9 million for Q3 2025 at Sunshine Biopharma, up from $3.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $18.9 million in Q3 2022 and bottomed at $12254.0 in Q3 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $3.8 million, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Shares Outstanding (Weighted Average) crashed 99.94% in 2023, then soared 10244.09% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $2.6 million in 2021, then skyrocketed by 481.18% to $15.2 million in 2022, then plummeted by 99.92% to $12825.0 in 2023, then surged by 5371.73% to $701749.0 in 2024, then surged by 459.35% to $3.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SBFM at $3.9 million in Q3 2025, $3.6 million in Q2 2025, and $2.7 million in Q1 2025.